BFO
VIVO

Boston Family Office’s Meridian Bioscience Inc VIVO Stock Holding History

Boston Family Office’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-103,174
Closed -$2.13M – 260
2014
Q2 		$2.13M Sell
103,174
-931
-0.9% -$19.1K 0.27% 103
2014
Q1 		$2.27M Buy
104,105
+420
+0.4% +$9.63K 0.3% 95
2013
Q4 		$2.75M Buy
103,685
+500
+0.5% +$12.3K 0.36% 85
2013
Q3 		$2.44M Buy
103,185
+3,585
+4% +$83.7K 0.35% 84
2013
Q2 		$2.14M Buy
+99,600
New +$2.15M 0.33% 89

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Boston Family Office's VIVO Position: Q3 2014 in Review

Boston Family Office sold out of Meridian Bioscience Inc (VIVO) in Q3 2014, closing a stake of 103,174 shares — an estimated $2.13M sold.

Boston Family Office first reported a position in VIVO in Q2 2013 and held it in 5 quarters. The position peaked at $2.75M in Q4 2013. 161 funds tracked by Wall St. Rank hold VIVO as of Q3 2014.

  • Boston Family Office reported no remaining Meridian Bioscience Inc position as of Q3 2014 after selling out during the quarter.
  • Boston Family Office sold 103,174 Meridian Bioscience Inc shares in Q3 2014, an estimated $2.13M.
  • Boston Family Office first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 5 quarters.
  • Boston Family Office's Meridian Bioscience Inc position peaked at $2.75M in Q4 2013.
  • 161 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2014.

Based on Boston Family Office's 13F filing for Q3 2014, filed 31 Oct 2014.